Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

BACKGROUND: Microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) tumours have a high response rate to immunotherapy. Antitumour activity and safety of serplulimab, a novel humanised anti-PD-1 monoclonal antibody, were evaluated in this phase II study. METHODS: In this ongoing, sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Li, Jin, Zhong, Haijun, Jin, Chuan, Chen, Lili, Yuan, Xianglin, Fan, Qingxia, Chen, Kehe, Cao, Peiguo, Xiao, Jianjun, Jiang, Da, Zhang, Tao, Zhang, Hongyu, Wang, Xicheng, Wang, Wei, Han, Lin, Wang, Qingyu, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726893/
https://www.ncbi.nlm.nih.gov/pubmed/36261583
http://dx.doi.org/10.1038/s41416-022-02001-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726893/
https://www.ncbi.nlm.nih.gov/pubmed/36261583
http://dx.doi.org/10.1038/s41416-022-02001-3

Ejemplares similares